Cancer Screening Ages – When to Start Each Test

Most cancer screenings start between age 21 and 50 depending on the cancer type. Cervical cancer screening begins at 21, colorectal screening at 45, breast mammograms at 40, and lung CT scans at 50 for qualifying high-risk smokers. Talk to your doctor if you have a family history that may move these start dates earlier.

What Age Does Each Major Screening Actually Begin?

Cancer screening start ages vary significantly by cancer type, risk level, and the recommending organization. The table below reflects current U.S. Preventive Services Task Force (USPSTF) guidelines, which are the federal advisory standards most U.S. insurers use to determine no-cost preventive coverage under the Affordable Care Act.

These numbers apply to average-risk adults in the United States. Individuals with a first-degree relative (parent or sibling) diagnosed with a given cancer may need to start screening 10 years before that relative’s diagnosis age.

Age calculator is available online for free, at AgeFinder. This free age calculator computes age in terms of years, months, weeks, days, hours, minutes, and seconds, given a date of birth.

How Screening Guidelines Differ Between Major U.S. Organizations

One of the most confusing aspects of cancer screening is that major medical organizations do not always agree on when to start or how often to screen. These differences are not errors. They reflect genuine disagreement about how to weigh the benefits of early detection against the harms of overdiagnosis, false positives, and unnecessary procedures.

Understanding that your doctor may follow one organization’s guidelines while your insurer uses another helps explain why recommendations you read online sometimes differ from what you are told at a clinic visit.

Breast Cancer Screening: The Age 40 Debate and What It Means for You

The USPSTF updated its breast cancer recommendation in 2024, lowering the suggested start age from 50 to 40 for women at average risk. This shift reflects research demonstrating that earlier screening catches more tumors at treatable stages, particularly in Black women, who statistically face a higher rate of aggressive breast cancer at younger ages.

The American Cancer Society recommends that women have the option to start annual mammograms at 40, with a firm recommendation beginning at 45, then transitioning to every 2 years at age 55 if preferred. The difference between organizations comes down to how they weigh the benefit of early detection against the risk of false positives (results that suggest cancer when none exists), which lead to additional imaging and sometimes unnecessary biopsies.

Women with dense breast tissue, a condition where more of the breast is made up of glandular and fibrous tissue than fat, face a higher lifetime cancer risk and may benefit from supplemental ultrasound or MRI screening. Your doctor can advise whether your mammogram report indicates dense tissue.

What Dense Breast Tissue Means for Your Screening Schedule

Dense breasts affect approximately 40 to 50 percent of women who undergo mammography. Dense tissue appears white on a mammogram, as does a tumor, which means cancers can be harder to spot. As of 2023, the FDA requires mammography facilities to notify all patients of their breast density category in plain language.

There are four density categories assigned after a mammogram:

1. Almost entirely fatty (least dense; easiest to read).
2. Scattered areas of fibroglandular density.
3. Heterogeneously dense (may obscure small masses).
4. Extremely dense (highest masking effect; highest associated cancer risk).

Women in categories 3 or 4 should discuss supplemental screening options with their provider. Supplemental breast ultrasound is covered by law in 38 states as of 2024. Breast MRI is typically reserved for women with a greater than 20 percent lifetime risk of breast cancer, including BRCA mutation carriers.

Breast Cancer Screening After Treatment

Women who have already been treated for breast cancer follow a different surveillance schedule than those undergoing primary prevention screening. After completing treatment, most oncologists recommend a clinical breast exam every 6 to 12 months for 5 years, then annually thereafter. Mammograms are typically recommended annually, starting 6 to 12 months after radiation therapy if applicable. Women who had breast-conserving surgery (lumpectomy) rather than mastectomy retain breast tissue that requires continued imaging.

Colorectal Cancer: Why the Start Age Dropped to 45

Colorectal cancer screening now begins at age 45, not 50 as it was prior to 2021, because rates of colon and rectal cancer in adults under 50 have been rising steadily since the 1990s. The USPSTF and the ACS both updated guidelines in response to this trend.

You have meaningful choices in how you screen for colorectal cancer. Not every method requires a colonoscopy, which is a procedure where a doctor inserts a flexible tube with a camera into the colon to look for polyps (small growths that can become cancerous).

Your main options:

1. Colonoscopy every 10 years (the gold standard; allows removal of polyps during the same procedure).
2. Flexible sigmoidoscopy every 5 years (examines only the lower portion of the colon).
3. Stool DNA test (Cologuard) every 1-3 years (a home test that detects cancer-related DNA and blood in stool).
4. Fecal immunochemical test (FIT) annually (a simple home stool blood test).
5. CT colonography every 5 years (a virtual colonoscopy using imaging rather than a scope).

If a stool-based test returns a positive result, a follow-up colonoscopy is required. People with inflammatory bowel disease or a family history of colorectal cancer may need screening starting at 40 or even earlier.

What Happens If Polyps Are Found

Not all polyps are equally concerning. Understanding the type found changes your follow-up schedule significantly.

Knowing your polyp type after a colonoscopy gives you a precise personal timeline rather than relying on population-level averages. Ask your gastroenterologist for the pathology report in plain language.

Lung Cancer Screening Criteria: Age Is Only Part of the Equation

Lung cancer screening is age-gated and risk-gated, meaning you must meet both criteria to qualify for covered, no-cost screening. The USPSTF recommends annual low-dose CT (LDCT) scans for adults who meet all three of the following conditions:

• Age 50 to 80.
• 20 pack-year smoking history (pack-years are calculated by multiplying the number of packs smoked per day by the number of years smoked; a person who smoked 1 pack per day for 20 years has a 20 pack-year history).
• Currently smoke or quit within the past 15 years.

Lung cancer causes more deaths annually in the United States than breast, prostate, and colorectal cancers combined. Annual LDCT screening has been shown to reduce lung cancer mortality by 20% in high-risk individuals compared to chest X-rays alone. Screening stops at age 80 or if a person has not smoked for more than 15 years.

Key Finding: Annual low-dose CT screening for qualifying adults remarkably reduces lung cancer death rates by 20%, making it one of the most impactful preventive tools available for high-risk smokers.

Never-Smokers and Lung Cancer Risk

Most lung cancer screening programs in the U.S. are built around smoking history, yet approximately 10 to 15 percent of lung cancer diagnoses occur in people who have never smoked. Never-smokers who develop lung cancer are more likely to be women, Asian Americans, and people with radon exposure, occupational asbestos exposure, or a family history of lung cancer.

Currently, the USPSTF does not recommend routine LDCT screening for never-smokers. However, the National Comprehensive Cancer Network (NCCN) includes a broader set of risk factors, such as radon or occupational exposure and family history, in its criteria for lung cancer screening consideration. If you are a never-smoker with significant other risk factors, ask your doctor whether NCCN-based risk assessment applies to you.

What to Do If a Lung Nodule Is Found

A pulmonary nodule (a small spot on the lung, typically less than 3 centimeters in diameter) is a common incidental finding on LDCT screening. The vast majority of nodules are benign (non-cancerous), caused by past infections, scar tissue, or inflammation.

Follow-up depends on nodule size:

• Less than 6 mm: Low-risk; typically no immediate follow-up needed.
• 6 to 8 mm: Follow-up CT in 3-6 months.
• Greater than 8 mm: PET scan or biopsy may be recommended.
• Rapidly growing nodule: Prompt evaluation regardless of size.

The Lung-RADS system (Lung Imaging Reporting and Data System), developed by the American College of Radiology, standardizes how radiologists categorize and communicate nodule findings to reduce variation in follow-up decisions.

Cervical Cancer Screening Ages: When Pap Smears and HPV Tests Apply

Cervical cancer screening starts at age 21 regardless of sexual activity history, and the type of test recommended changes as you get older. Cervical cancer is caused almost entirely by persistent infection with HPV (human papillomavirus, a sexually transmitted virus with more than 150 known strains).

Women who have had a total hysterectomy (surgical removal of the uterus and cervix) for reasons unrelated to cancer generally do not need continued cervical screening. Women vaccinated against HPV still require routine screening because vaccines do not protect against all cancer-causing HPV strains.

HPV Vaccination and Its Relationship to Screening

The HPV vaccine (Gardasil 9) protects against 9 HPV strains, including the two highest-risk strains (types 16 and 18) responsible for approximately 70 percent of cervical cancers. The CDC recommends the vaccine for all children at age 11 or 12, with catch-up vaccination through age 26 for those not previously vaccinated.

Adults aged 27 to 45 may discuss vaccination with their doctor, though the benefit decreases with age due to likely prior HPV exposure. Importantly, HPV vaccination does not eliminate the need for routine cervical cancer screening. Vaccinated women should continue Pap smears and HPV co-testing on the same schedule as unvaccinated women.

What Abnormal Cervical Screening Results Mean

An abnormal Pap smear does not mean you have cervical cancer. Results are categorized by a system called the Bethesda System, and each category triggers a different follow-up pathway.

Most abnormal results resolve on their own, particularly in younger women whose immune systems often clear HPV infections without treatment.

Prostate Cancer Screening: A Shared Decision, Not a Blanket Rule

Prostate cancer screening with the PSA (prostate-specific antigen) blood test does not carry a universal start age mandate in the way other screenings do. The USPSTF gives prostate cancer screening a Grade C recommendation for men aged 55 to 69, meaning the decision should be made individually after a conversation about benefits and potential harms.

PSA testing can detect prostate cancer early, but it also produces false positives that lead to unnecessary biopsies and can identify slow-growing cancers that would never have caused harm, a concept called overdiagnosis. For Black men, who face 2.3 times the prostate cancer death rate of white men, many urologists and the ACS recommend beginning the conversation about PSA screening at 40 to 45.

Men with a family history of prostate cancer in a first-degree relative diagnosed before 65 should discuss early screening at 40 with their doctor.

Understanding PSA Numbers

A PSA test result is measured in nanograms per milliliter (ng/mL) of blood. There is no universally agreed cutoff for what constitutes an abnormal PSA level, because PSA rises naturally with age and prostate size. However, general reference ranges used in clinical practice include:

A single elevated PSA does not confirm cancer. Benign prostatic hyperplasia (BPH, meaning a non-cancerous enlargement of the prostate), prostatitis (prostate inflammation), recent sexual activity, and even vigorous cycling can temporarily elevate PSA levels. Doctors often repeat the test before recommending a biopsy.

Beyond PSA: Additional Prostate Cancer Tests

Several newer tools help doctors decide whether an elevated PSA warrants a biopsy, reducing unnecessary procedures:

• PSA density: Compares PSA level to prostate size measured by MRI or ultrasound.
• PSA velocity: Tracks how quickly PSA rises over time; rapid increases are more concerning.
• Free PSA ratio: Cancer is more likely when the free (unbound) fraction of PSA is low relative to total PSA.
• 4Kscore test: A blood test combining four prostate biomarkers to estimate the probability of high-grade cancer.
• Prostate Health Index (PHI): An FDA-cleared blood test that improves specificity for high-grade prostate cancer detection.
• mpMRI (multiparametric MRI): An advanced imaging technique used before biopsy to identify suspicious regions and guide targeted sampling.

Skin Cancer: No Federally Mandated Start Age, but Annual Checks Matter

Skin cancer is the most commonly diagnosed cancer in the United States, with more than 5 million cases treated annually. Despite this, the USPSTF currently finds insufficient evidence to recommend universal skin cancer screening for the general adult population, giving it an I statement (meaning not enough data to make a recommendation either way).

Dermatologists widely recommend annual full-body skin exams for individuals with any of the following risk factors:

• Personal history of skin cancer.
• More than 50 moles on the body.
• Family history of melanoma (the most dangerous form of skin cancer).
• History of significant sunburns, especially before age 18.
• Use of tanning beds.
• Fair skin, light eyes, or red or blonde hair.

Melanoma, when caught at Stage I, has a 5-year survival rate above 98%. When caught at Stage IV, that rate drops to approximately 30%. Self-examination monthly and professional skin checks annually are practical steps anyone can take regardless of formal guideline recommendations.

The ABCDE Rule for Self-Examination

Monthly self-skin checks are a practical complement to annual professional exams. Dermatologists teach the ABCDE rule as a framework for spotting potentially dangerous moles or lesions at home:

• A – Asymmetry: One half does not match the other half.
• B – Border: Edges are irregular, ragged, notched, or blurred.
• C – Color: Variation in color from one area to another, including shades of brown, black, red, white, or blue.
• D – Diameter: Larger than 6 millimeters (about the size of a pencil eraser), though melanomas can be smaller.
• E – Evolving: Any change in size, shape, color, or new symptom such as bleeding or itching.

Any lesion that meets one or more of these criteria warrants evaluation by a dermatologist. The American Academy of Dermatology (AAD) offers free ABCDE reference guides and mole-mapping resources online.

Ovarian Cancer: Why There Is No Routine Screening Test

Ovarian cancer has no recommended routine screening for average-risk women, a fact that surprises many patients. The USPSTF recommends against routine ovarian cancer screening with either the CA-125 blood test (a protein marker elevated in some ovarian cancers) or transvaginal ultrasound in asymptomatic women at average risk, giving it a Grade D recommendation.

The reason is that both available tests produce a high rate of false positives in average-risk women, leading to unnecessary surgical procedures with meaningful complication risks, without evidence of reduced mortality. This does not mean ovarian cancer is untreatable when caught early; it means current available tests are not accurate enough at the population level to do more good than harm.

Women at high risk, particularly those carrying BRCA1 or BRCA2 mutations or with Lynch syndrome, may be offered surveillance with CA-125 and transvaginal ultrasound starting at age 30 to 35, though even in this group the evidence for mortality benefit is limited. Prophylactic salpingo-oophorectomy (surgical removal of the ovaries and fallopian tubes) is often discussed with BRCA carriers as a risk-reduction strategy, typically recommended between ages 35 and 40 for BRCA1 carriers and between 40 and 45 for BRCA2 carriers.

Symptoms that should prompt evaluation regardless of screening status:

• Persistent bloating lasting more than 2 weeks.
• Pelvic or abdominal pain.
• Difficulty eating or feeling full quickly.
• Urinary urgency or frequency.

These symptoms overlap with many benign conditions, but when they are new and persistent, they warrant a visit to a gynecologist.

Endometrial (Uterine) Cancer: Symptom-Driven Rather Than Routine Screening

Endometrial cancer, the most common gynecologic cancer in the United States with approximately 66,000 new diagnoses annually, has no recommended routine screening for average-risk women. Unlike cervical cancer, endometrial cancer is not reliably detected by Pap smear.

The reason routine screening is not recommended is that endometrial cancer commonly causes early symptoms, particularly abnormal uterine bleeding, which prompts diagnosis at an early and highly treatable stage in many women. The 5-year survival rate for localized endometrial cancer is approximately 95%.

Women who should discuss earlier surveillance:

• Carriers of Lynch syndrome mutations (MLH1, MSH2, MSH6, PMS2, EPCAM genes): annual endometrial biopsy starting at age 30 to 35.
• Women with hereditary nonpolyposis colorectal cancer (HNPCC) syndrome.
• Women who have used unopposed estrogen therapy (estrogen without progesterone) long-term.
• Women with a BMI over 40 (obesity significantly increases endometrial cancer risk).

Any postmenopausal bleeding is abnormal and requires medical evaluation, regardless of age or screening history.

Oral, Head, and Neck Cancer Screening

Oral cancer, which includes cancers of the mouth, tongue, lips, throat, salivary glands, and part of the pharynx, is diagnosed in approximately 54,000 Americans annually. Head and neck cancers as a broader group affect the oral cavity, oropharynx (back of the throat), larynx (voice box), and nasal passages.

There is no USPSTF recommendation for routine oral cancer screening for the general population. However, dentists routinely perform visual oral examinations during checkups and are often the first clinicians to spot suspicious lesions. The American Dental Association recommends that all adults receive an oral cancer screening as part of routine dental care.

Key risk factors that raise your personal priority for oral cancer screening:

• Tobacco use (smoking or smokeless tobacco) accounts for approximately 75 percent of oral cancers.
• Heavy alcohol consumption.
• HPV infection, particularly HPV-16, now linked to a significant and growing proportion of oropharyngeal cancers in non-smokers.
• Sun exposure (lip cancer specifically).
• Age over 40 combined with tobacco and alcohol use.

The rise of HPV-related oropharyngeal cancer (cancer of the back of the throat, tonsils, and base of the tongue) in non-smoking adults has changed the demographic profile of head and neck cancers in the U.S. Men are 4 times more likely than women to develop HPV-related oropharyngeal cancer.

Pancreatic Cancer: High-Risk Surveillance Only

Pancreatic cancer has no recommended routine screening for average-risk adults, and the USPSTF recommends against screening in this population. The pancreas sits deep in the abdomen, and currently available imaging tools have insufficient sensitivity and specificity to reliably catch early pancreatic cancer before symptoms develop.

However, individuals at significantly elevated hereditary risk do benefit from structured surveillance. The International Cancer of the Pancreas Screening (CAPS) Consortium recommends starting pancreatic surveillance at age 40 to 50 or 10 years before the youngest affected relative for individuals with:

• BRCA2 gene mutation with at least one first-degree relative with pancreatic cancer.
• BRCA1 mutation with two or more affected relatives.
• PALB2 mutation.
• Lynch syndrome with a family history of pancreatic cancer.
• Familial atypical multiple mole melanoma (FAMMM) syndrome with a CDKN2A mutation.
• Peutz-Jeghers syndrome (a condition causing intestinal polyps and elevated cancer risk across multiple organs).
• Hereditary pancreatitis (chronic pancreatic inflammation with a genetic basis).

Surveillance typically involves alternating endoscopic ultrasound (EUS) and MRI/MRCP (magnetic resonance cholangiopancreatography, a specialized MRI of the bile ducts and pancreas) annually. These exams are best performed at specialized centers with experience in pancreatic surveillance programs.

Stomach (Gastric) Cancer Screening in the U.S.

The United States does not have a population-wide gastric cancer screening program, unlike countries such as Japan and South Korea where stomach cancer rates are significantly higher and national endoscopy programs are standard practice. In the U.S., gastric cancer is relatively uncommon in the general population, with approximately 26,000 new cases annually.

Screening or surveillance is considered for specific high-risk groups:

• Individuals with hereditary diffuse gastric cancer (HDGC) syndrome caused by CDH1 gene mutations: annual upper endoscopy starting at age 18 to 20, with prophylactic total gastrectomy (surgical stomach removal) often discussed.
• People with familial adenomatous polyposis (FAP): regular upper endoscopy to monitor gastric and duodenal polyps.
• Individuals with a personal history of gastric adenomas or intestinal metaplasia (a precancerous change in stomach lining).
• People with confirmed H. pylori infection (a bacterial infection strongly associated with gastric cancer): eradication treatment and possible follow-up endoscopy.

Korean American and Japanese American communities have higher gastric cancer incidence rates than the general U.S. population, and some gastroenterologists recommend individualized risk discussions for these patients even without hereditary syndromes.

High-Risk Individuals: When Earlier Screening Changes Everything

Standard start ages apply to average-risk adults, but several genetic and family history factors significantly pull those timelines forward. Genetic counseling, which involves a certified specialist evaluating your family history and sometimes ordering genetic tests, can clarify whether you qualify for earlier or more intensive surveillance.

Conditions that typically move screening earlier:

Identifying a hereditary cancer syndrome early through genetic testing can be genuinely life-changing. It not only guides your own screening schedule but also alerts blood relatives who may carry the same mutation and benefit from earlier testing.

When to Consider Genetic Counseling

Genetic counseling is worth requesting if any of the following apply to your personal or family history:

• A first-degree relative diagnosed with cancer before age 50.
• Multiple relatives on the same side of the family with the same or related cancers.
• A relative with a known hereditary cancer gene mutation (BRCA1, BRCA2, MLH1, etc.).
• A personal history of two or more primary cancers.
• A male relative diagnosed with breast cancer (rare and often hereditary).
• Ovarian, pancreatic, or metastatic prostate cancer at any age in a close relative.
• Ashkenazi Jewish ancestry, which carries elevated rates of BRCA1 and BRCA2 mutations (approximately 1 in 40 individuals).

Genetic counselors are certified professionals trained to interpret complex hereditary risk information and help patients understand testing options, results, and implications for family members. Referrals can be obtained through your primary care doctor or through the National Society of Genetic Counselors (NSGC) online directory.

Racial and Ethnic Disparities in Cancer Screening

Cancer screening guidelines are built on population-average data, but cancer risk, incidence, and outcomes are not equally distributed across racial and ethnic groups in the United States. These differences are driven by a combination of genetic factors, access barriers, historical underrepresentation in clinical trials, and systemic inequities in healthcare delivery.

Addressing these disparities requires both individual awareness and systemic change. Patients from higher-risk groups should feel empowered to raise their specific risk profile with their doctor and ask whether guideline recommendations fully reflect their background.

Insurance Coverage and Cost Considerations

Under the Affordable Care Act (ACA), preventive cancer screenings with an A or B grade from the USPSTF must be covered at no cost to the patient by most private health insurance plans, with no deductible or copay. This includes mammograms, cervical cancer screening, colorectal cancer screening, and lung cancer LDCT for qualifying individuals.

Medicare covers cervical cancer screening every 24 months (or annually for high-risk women), mammograms annually starting at 40, colorectal cancer screening through multiple methods, lung cancer LDCT annually for qualifying beneficiaries, and PSA testing annually for men 50 and older.

Uninsured patients can access low-cost or free cancer screenings through programs including the CDC’s National Breast and Cervical Cancer Early Detection Program (NBCCEDP), which serves low-income and uninsured women across all 50 states. Community health centers funded by the federal Health Resources and Services Administration (HRSA) also offer sliding-scale cancer screening services.

What the 2022 Braidwood Decision Means for ACA Coverage

A 2022 federal court ruling in Texas (Braidwood Management v. Becerra) challenged the ACA’s requirement that insurers cover preventive services rated A or B by the USPSTF at no cost. The ruling was appealed, and as of 2024 the case remains in litigation. Depending on the final outcome, some preventive screening coverage requirements could change.

Until a final ruling is issued by the Supreme Court, existing ACA coverage requirements remain in effect for most plans. Patients should contact their insurer directly to confirm current coverage before scheduling a screening, particularly for higher-cost procedures such as colonoscopy, breast MRI, or LDCT lung screening.

How to Reduce Out-of-Pocket Costs If You Are Underinsured

Even with insurance, some patients face unexpected costs when a screening leads to a diagnostic procedure. A colonoscopy that begins as a preventive screening can be billed as a diagnostic procedure if a polyp is removed, which may trigger cost-sharing requirements.

Practical steps to reduce costs:

• Ask your insurer in writing whether a colonoscopy with polypectomy is billed as preventive or diagnostic under your plan.
• Use in-network providers confirmed before your appointment.
• For stool-based tests, ask your doctor to prescribe a FIT test as a lower-cost alternative to Cologuard.
• Apply for manufacturer patient assistance programs if cost is a barrier to genetic testing.
• Contact your state health department for free or reduced-cost screening programs beyond the federal NBCCEDP.

Screening After Cancer Diagnosis: Surveillance Is Different from Screening

Once a person has been diagnosed with and treated for cancer, they enter a phase called surveillance, which is different from primary prevention screening. Surveillance focuses on detecting cancer recurrence (the return of the original cancer) and monitoring for second primary cancers (new and unrelated cancers that can develop in cancer survivors, sometimes as a consequence of prior treatment).

Cancer survivors have different risks than the general population and follow individualized schedules that are determined by their oncology team. Common surveillance considerations include:

• Breast cancer survivors: Mammogram of remaining breast tissue annually; clinical exam every 6-12 months for 5 years, then annually.
• Colorectal cancer survivors: Colonoscopy at 1 year after surgery, then at 3 years, then every 5 years if normal.
• Cervical cancer survivors: Pap smear and pelvic exam every 3-6 months for 2 years, then annually.
• Prostate cancer survivors: PSA monitoring every 6-12 months with imaging as indicated.
• Lung cancer survivors: CT chest imaging every 6 months for 2 years, then annually.

Chemotherapy and radiation therapy can increase the risk of secondary cancers in treated organs and surrounding areas. Survivors who received chest radiation (for example, for lymphoma) are at elevated risk of breast cancer and heart disease and may be enrolled in high-intensity surveillance programs.

Building Your Personal Screening Timeline

Knowing the standard ages is genuinely useful, but your personal timeline should account for your own risk profile. A productive conversation with your primary care physician or OB-GYN should cover your family cancer history, your smoking status, your BMI (body mass index, a measure of body weight relative to height linked to several cancers), and any prior abnormal screening results.

A practical framework for average-risk adults:

1. Age 21: Begin cervical cancer Pap smears every 3 years.
2. Age 40: Begin annual mammograms (women); discuss PSA with doctor (men at higher risk).
3. Age 45: Begin colorectal cancer screening (method of your choice).
4. Age 50: Discuss PSA testing (men at average risk); begin lung LDCT if you meet smoking criteria.
5. Age 55: Discuss transitioning mammograms to every 2 years if preferred.
6. Age 65: Cervical screening may stop if you have had consistently normal results.
7. Age 75: Discuss whether continued colorectal and breast screening is appropriate with your doctor based on your overall health.
8. Age 80: Lung cancer LDCT screening ends per USPSTF guidelines.

Adhering to this schedule across your lifetime gives you the best available evidence-based protection against late-stage cancer diagnoses, when treatment is both harder and significantly less effective.

Keeping Your Own Screening Records

Many patients rely entirely on their healthcare provider to track screening history, but gaps are common, especially when changing doctors or insurance plans. Maintaining your own written or digital record of every cancer screening, including the date, result, and recommended follow-up interval, puts you in control of your preventive care timeline.

A simple personal record should include:

• Type of screening and date performed.
• Facility or provider who performed it.
• Result (normal, abnormal, or pending follow-up).
• Next recommended screening date.
• Any follow-up procedures performed and their results.

Patients who track their own screening history are better positioned to notice when a recommended test has been delayed and to advocate for timely care at every provider visit.

FAQs

What age should I start getting cancer screenings?

The most common screening start ages in the U.S. are 21 for cervical cancer, 40 for breast cancer, 45 for colorectal cancer, and 50 for lung cancer in qualifying smokers. Your personal start age may be earlier if you have a family history or carry a known genetic mutation.

When should women start getting mammograms?

The USPSTF recommends that women at average risk begin annual mammograms at age 40. The American Cancer Society suggests women have the option to start at 40 with a firm recommendation at 45. Women with a BRCA1 or BRCA2 gene mutation may need to start as early as age 25.

At what age do you start getting a colonoscopy?

Most guidelines, including those from the USPSTF and the American Cancer Society, now recommend starting colonoscopy screening at age 45 for average-risk adults. People with a first-degree relative diagnosed with colorectal cancer should start 10 years before that relative’s diagnosis age.

When should men start prostate cancer screening?

Men at average risk should discuss PSA testing with their doctor between ages 55 and 69. Black men and men with a first-degree relative diagnosed with prostate cancer before age 65 should have that conversation starting at age 40.

What age does lung cancer screening start?

Lung cancer screening with annual low-dose CT starts at age 50 for adults who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years. Screening is recommended until age 80.

Does insurance cover cancer screenings with no copay?

Yes. Under the Affordable Care Act, cancer screenings with an A or B USPSTF grade must be covered at $0 cost to the patient by most private insurance plans, with no deductible or copay applied. Medicare also covers most major cancer screenings for eligible beneficiaries. However, the ACA coverage requirement is currently under legal challenge, so confirming coverage with your insurer before scheduling is advisable.

When can women stop getting Pap smears?

Women aged 65 and older who have had 3 consecutive normal Pap smears or 2 consecutive normal HPV co-tests within the prior 10 years, with no abnormal results in that time, can generally stop cervical cancer screening. Women who have had a hysterectomy removing the cervix for non-cancer reasons also typically do not need further Pap smears.

What cancers should be screened for in your 20s?

Cervical cancer is the primary cancer with a screening recommendation in your 20s, starting at age 21 with a Pap smear every 3 years. No other routine cancer screenings are recommended for average-risk adults in their 20s, though people with specific genetic syndromes like Lynch syndrome may begin colorectal screening in their early 20s.

At what age should you start skin cancer screenings?

There is no federally recommended universal start age for skin cancer screening. Dermatologists generally recommend annual full-body skin exams for anyone with risk factors including a personal or family history of melanoma, more than 50 moles, or significant sun exposure history. Anyone can begin at any age, and monthly self-exams using the ABCDE rule are recommended for all adults.

How often do you need a mammogram after 50?

After age 50, the USPSTF recommends mammograms every 2 years through age 74 for average-risk women. The American Cancer Society supports continuing annual mammograms as long as a woman is in good health and has a life expectancy of 10 or more years. Women with dense breast tissue or other risk factors may benefit from annual imaging regardless of age.

What is the recommended age for a first colonoscopy if there is no family history?

For adults with no personal or family history of colorectal cancer or polyps, the recommended age for a first colonoscopy is 45. If the colonoscopy shows no polyps or concerns, the next one is typically not needed for 10 years.

Does family history of cancer change when screening starts?

Yes, significantly. A first-degree relative diagnosed with colorectal cancer means you should start screening at age 40 or 10 years before their diagnosis age, whichever is earlier. A BRCA gene mutation in your family can move breast cancer screening to as early as age 25. Genetic counseling helps clarify your personal timeline.

What cancer screenings are recommended at age 50?

At age 50, average-risk adults should confirm they have begun colorectal cancer screening (which now starts at 45), and qualifying smokers should begin annual lung CT scans. Men should discuss PSA testing. Women should continue annual or biennial mammograms. A conversation with your doctor at 50 is a valuable checkpoint to review your full screening schedule.

Is there a screening test for ovarian cancer?

No routine screening test for ovarian cancer is recommended for average-risk women. The USPSTF recommends against routine screening with CA-125 blood tests or transvaginal ultrasound because current tests produce too many false positives without evidence of reduced mortality. Women at high risk due to BRCA mutations or Lynch syndrome should discuss surveillance options with a gynecologic oncologist starting around age 30 to 35.

What is the difference between cancer screening and cancer surveillance?

Cancer screening refers to testing asymptomatic people who have never had cancer, with the goal of early detection. Cancer surveillance refers to monitoring people who have already been diagnosed and treated for cancer, with the goal of detecting recurrence or new primary cancers. Surveillance schedules are individualized by an oncology team and differ substantially from standard population screening guidelines.

Should I get genetic testing to determine my cancer screening schedule?

Genetic testing may be appropriate if you have a strong family history of cancer, a relative with a known hereditary mutation, or a personal history of multiple cancers. A genetic counselor can review your history and recommend specific tests. Positive results can significantly change your recommended screening start ages, the types of tests used, and the frequency of surveillance across multiple cancer types.

What is a pack-year and how do I calculate mine for lung cancer screening?

A pack-year is a unit used to measure cumulative tobacco exposure, calculated by multiplying the number of packs smoked per day by the number of years smoked. Smoking 1 pack per day for 20 years equals 20 pack-years, as does smoking 2 packs per day for 10 years. You need at least 20 pack-years to qualify for lung cancer screening under USPSTF guidelines.

What happens if I miss a recommended cancer screening?

Missing a single screening cycle does not eliminate your protection, but it does extend the window during which an early cancer could go undetected. The priority is to reschedule as soon as possible rather than wait for your next routine physical. If cost or access was the barrier, contact your local health department or community health center for low-cost or no-cost alternatives.

Do men need any cancer screenings besides prostate and colorectal?

Yes. Men should also consider lung cancer LDCT if they meet smoking criteria, skin cancer exams if they have risk factors, and oral cancer screening as part of routine dental care. Men can also develop breast cancer, though it is rare, accounting for about 1 percent of all breast cancers. Men with a strong family history or a BRCA2 mutation should discuss breast awareness and possible clinical exams with their doctor starting at age 35.

Why do cancer screening guidelines change over time?

Guidelines change when new clinical trial data, longer follow-up studies, or updated risk-benefit analyses become available. Organizations like the USPSTF conduct systematic reviews on a rolling basis and update recommendations when evidence shifts. The 2021 colorectal screening age change to 45 and the 2024 breast screening age change to 40 are both examples of guidelines evolving in response to new population data. Checking for updated guidelines every few years with your doctor ensures your schedule reflects current evidence.